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We describe a simple method for bone engineering using biodegradable scaffolds with mesenchymal stem
cells derived from human induced-pluripotent stem cells (hiPS-MSCs). The hiPS-MSCs expressed
mesenchymal markers (CD90, CD73, and CD105), possessed multipotency characterized by tri-lineages
differentiation: osteogenic, adipogenic, and chondrogenic, and lost pluripotency – as seen with the loss of
markersOCT3/4 andTRA-1-81 – and tumorigenicity. However, these iPS-MSCs are still positive formarker
NANOG. We further explored the osteogenic potential of the hiPS-MSCs in synthetic polymer
polycaprolactone (PCL) scaffolds or PCL scaffolds functionalized with natural polymer hyaluronan and
ceramic TCP (PHT) both in vitro and in vivo. Our results showed that these iPS-MSCs are functionally
compatible with the two 3D scaffolds tested and formed typically calcified structure in the scaffolds. Overall,
our results suggest the iPS-MSCs derived by this simplemethod retain fully osteogenic function and provide
a new solution towards personalized orthopedic therapy in the future.
M
esenchymal stem cells (MSCs), which possess multilineage potential of differentiating to mesenchymal
tissues such as bone, fat, and cartilage, represent an important renewable cell source for orthopedic
therapy1. However, the clinical applications of autologous transplantation of MSCs derived from adult
tissues, such as bone marrow and adipose tissue, are hampered by their limited proliferating capacity, which
decreases with increasing donor age2.
Induced pluripotent stem (iPS) cells, generated by ectopically expressing certain transcription factors (typically
Oct3/4, Sox2, Klf4 and c-Myc3), resemble ES cells in a pluripotent state4. Methods for reprogramming human
somatic cells into iPS cells have dramatically improved over the last five years5. Non-integrating methods by e.g.
direct mRNAs or proteins transfection, and integration deficient virus are favored for clinically compliant
applications6–9. Mesenchymal stem cells derived from mouse or human iPS cells (iPS-MSCs) have been reported
by several groups10,11 and used for osteogenesis both in vitro and in vivo12, whichmakes iPS-MSCs a promising cell
source for studying orthopedic diseases, regenerative orthopedic therapy, and patient-specific cell therapy.
Moreover, the iPS-MSCs have greater capacity of cell proliferation than bone marrow-derived MSCs (over 10-
fold higher in telomerase activity) and are able to proliferate for 120 population doublings without losing self-
renewal capacity and MSC characteristics13.
Most MSCs derivations are achieved via the formation of three-dimensional embryoid bodies, which are
laborious, inefficient and uncontrollable for spontaneous differentiation14. Yen et al. have described a simple
method of differentiating human ES cells (hESCs) into MSCs by switching hES cells from ES medium to defined
medium, which consisted of DMEM-low glucose, 10% FBS, and 1% Penicillin/Streptomycin, followed by trypsi-
nization-based passaging15. In this study, we investigated whether this method can be applied to human iPS cells.
We also investigated the potential for combining iPS-MSCs and 3D orthopedic scaffolds made from biodegrad-
able polymer materials for bone engineering.
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Results
Generation of human iPSCs (hiPSCs) by mRNA reprogramming.
We firstly generated human iPSCs bymRNA reprogramming, which
is nonintegrating and clinically relevant. We transfected human
IMR90 fibroblasts (Fig. 1a) with modified mRNA cocktails.
Expression of Oct4, Sox2, and Klf4 were observed in transfected
cells 16 hours after transfection (Supplementary Fig. 1). Colonies
of human ES cell morphology (iPSC clones) first became visible 12
days after transfection with a modified mRNA reprogramming
cocktail and on day 20 roughly 100 iPSC clones were observed.
Clones with typical morphology of human ES cells were selected
for expansion (Fig. 1b). The iPS cells were positive for pluripotent
marker OCT4 (Fig. 1c) and NANOG (Fig. 1d), in parity with the H7
ES cell line (Fig. 1e and 1f), and were able to form teratoma in vivo
when injected into the immunosuppressed mouse (Fig. 1g).
One-step derivation of fibroblastic-like cells from hiPSCs. To
differentiate the iPSCs to MSCs, we switched the iPS cells from iPS
medium to medium consisting of DMEM-low glucose (Biological
Industries), 2 mM L-Glutamine, 1% penicillin/streptomycin, and
10% FBS (Gibco) as describe previously16. The iPSCs began to lose
the typical iPSC morphology and acquired a spindle-shaped
morphology at the border of the colonies in a few days (Fig. 2a
and 2b). After two weeks differentiation, the differentiated iPSCs
were passaged with trypsin/EDTA and resulted in a complete
morphological change of the cells to a fibroblastic shape after
passaging three times (Fig. 2c).
Characterization of hiPS-MSCs. To investigate whether the
fibroblastic-like cells differentiated from iPSCs were MSCs, these
cells (three passages: 3, 5, and 7) were analyzed by flow cytometry
for human mesenchymal makers (CD901, CD731, CD1051, CD34-,
and CD45-). The iPS-derived cells were indeed positive for CD90,
CD73, and CD105 and negative for CD34, and CD45 in all three
passages tested (Fig. 2d–2h, results from passage 7). These hiPS-
MSCs were actively proliferating and were further characterized as
karyotypically normal after splitting in vitro for 17 passages (Fig. 2i).
To test whether these cells loss the pluripotency of iPSCs, we
measured the expression of Oct3/4, NANOG, and TRA-1-81 in
two different passages (8 and 12) of iPS-MSCs by flow cytometry
analysis. The hiPS-MSCs were negative for OCT3/4 and TRA-1-81,
however positive for NANOG (Fig. 3). We furthermore tested the
hiPS-MSC-like cells for MSC pluripotency by investigating their
abilities of osteogenesis, adipogenesis, and chondrogenesis. For
osteogenesis, hiPS-MSCs (passage 4) were cultured in osteogenic
medium and were positive for alkaline phosphatase (ALP) from
day 7 (Supplementary Fig. 2b) but not control medium (Supple-
mentary Fig. 2a) and began to mineralize the extracellular matrix
(ECM) as determined by Alizarin red staining on day 14 (Fig. 4a).
For adipogenesis, Oil Red O staining demonstrated small lipid drop-
lets in the cytoplasm of differentiated hiPS-MSCs (Fig. 4b). After 3
weeks of culture in chondrogenic medium, pellet cultures of hiPS-
MSCs demonstrated red-purple proteoglycan-rich extracellular
matrix by toluidine blue staining (Fig. 4c), suggesting that the iPS-
derived cells hold MSCs properties and pluripotency.
The hiPS-MSCs formed calcified structures in scaffolds in vitro.
We further explored the possibility of using the hiPS-MSCs for
osteogenesis in 3D scaffolds. We firstly functionalized the PCL
scaffolds with hyaluronan, which could accelerate tissue repairing
by promoting the migration and differentiation of mesenchymal
cells17, and incorporated the inorganic component b-TCP to
improve the osteoconductivity and enhance bone tissue forma-
tion18. After fabrication of the PHT scaffolds, Hyaluronan/TCP
matrix homogenously covered and connected the PCL scaffold
fibers as seen by SEM scanning (Fig. 5a) .
Firstly, we investigated the viability of cells cultured on PHT scaf-
folds by confocal microscopy with CellTracker green and Hoechst
staining. One day after adding the hiPS-MSCs (passage 4) to the PHT
scaffolds, all cells were attaching well to the fibers (Fig. 5b).
Moreover, after culturing in proliferation medium for one week,
the hiPS-MSCs attached to and proliferated along the fibers of scaf-
folds (Fig. 5c). This indicates that the PHT scaffolds are suitable for
hiPS-MSCs growth given that it facilitates hiPS-MSCs initial attach-
ment onto the surface, spreading and subsequent proliferation.
We then investigated the osteogenic capacity of the iPS-MSCs in
PHT or PCL scaffolds by measuring the ALP activity and calcium
deposition during an osteoinduction period (21 days). Relative ALP
activity was calculated by normalizing to DNA contents (Fig. 5d). As
seen in Fig. 5d, hiPS-MSCs-seeded scaffolds cultured in osteogenic
medium significantly increased ALP activity throughout the osteoin-
duction period, irrespective of scaffolds. Notably, The ALP activity
also increased in hiPS-MSCs-seeded scaffolds cultured in prolifera-
tionmedium, suggesting that the PCL or PHT scaffolds are capable of
inducing ALP expression in MSCs. However, higher ALP activity
was observed in hiPS-MSC-seeded PHT or PCL scaffolds cultured
in osteogenic medium than in proliferation medium from day 7
onwards (Fig. 5d). ALP activity of the PHT scaffolds was signifi-
cantly higher than that of PCL in osteogenic medium on day 21
Figure 1 | Generation of human iPSCs by mRNA reprogramming.
Phase-contrast image of human fibroblasts (a) and mature iPSC clone (b).
(c–d) Immunohistochemistry of pluripotency markers: OCT4 (c) and
NANOG (d) in iPSCs. (e–f) Immunohistochemistry of pluripotency
markers: OCT4 (e) and NANOG (f) in H7 lines. (g) Teratoma formed in
SCID mice 8 weeks after injected with iPS cells.
www.nature.com/scientificreports
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(Fig. 5d). Calcium contents were measured to assess the extent of
matrix mineralization on the scaffolds. Total calcium content was
significantly (p, 0.05) higher on days 14 and 21 scaffolds in osteo-
genicmedium as compared to that in proliferationmedium (Fig. 5e).
Again, we observed the hiPS-MSCs-seeded PHT scaffolds had higher
calcium deposition than the corresponding PCL scaffolds (p, 0.05).
We also measured the expression of osteogenesis-related genes
following the induction of osteogenesis. Increase expression of
osteoblast markers, the transcription factor Runx2, alkaline phos-
phatase (ALP), extracellular matrix and structural proteins coding
gene Col1a1, and the bone-specific protein-osteocalcin coding gene
(OC) were observed in hiPS-MSC-seeded PHT or PCL scaffolds
cultured in osteogenic medium than in proliferation medium
(Fig. 6). Higher induction of ALP expression was observed in PHT
than in PCL scaffolds, which is consistent with the results of the ALP
activity assay.
Figure 2 | Generation and characterization of iPS-derived mesenchymal stem cells. Phase-contrast image of long-term cultured iPSC clone before
differentiation (a) intermediate phase of differentiating the iPS cells into MSCs (b) and complete differentiated fibroblast like cells (passage 3) (c).
(d–h) Flow cytometric analysis of mesenchymal markers (one representative of three individual passages, figure shown were from passage 7 hiPS-MSCs).
Black histograms: anti-CD90 (d) anti-CD73 (e) and anti-CD105 (f) and negative markers: anti-CD34 (g) and anti-CD45 (h). Gray histograms:
corresponding isotype controls (d–h). (i) karyotype of passage 17 iPS-MSCs.
www.nature.com/scientificreports
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Figure 3 | Analysis of pluripotentmarkers in the hiPS-MSCs. Flow cytometric analysis of pluripotentmarkers: OCT3/4,NANOG, andTRA-1-81. Green
histogram: unstained cell control; Blue histogram: isotope control; Red histogram: stained with markers against OCT3/4, NANOG, and TRA-1-81
respectively.
www.nature.com/scientificreports
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We furthermore characterized the formation of ECM at day 21 by
SEM. Scaffolds (PCL or PHT) seeded with iPS-MSCs and cultured in
basal proliferation medium have a clear cellular network with assoc-
iated ECM attached onto the rods and spanning across the pores of
the scaffolds (Fig. 7a and 7b). ECM formation was observed in the
PCL or PHT scaffolds cultured osteogenic medium (Fig. 7c and 7d)
or in controlmedium (Fig. 7a and 7b), respectively. The PCL scaffold
is a calcium-free scaffold (Fig. 7a). De novo calcium mineralization
was detected on PCL scaffold co-cultivated with iPS-MSCs in osteo-
genic medium by energy dispersive X-ray spectrometer/EDX
(Fig. 7c). The PHT scaffold contains calcium owing to the TCP.
Thus, calcium was detected both in proliferation and osteogenic
medium (Fig. 7b and 7d).
iPS-MSCs form ectopic bone in scaffolds in vivo. Finally, we
evaluated whether the iPS-MSCs seeded scaffolds could promote
ectopic bone formation in vivo. We subcutaneously implanted one
PCL or PHT scaffold with and without preseeded hiPS-MSCs
(passage 5) into each side of a nude mouse (Fig. 8a). Four mice
were used for each type of scaffolds. Twelve weeks after implanta-
tion, the scaffolds were well integrated into the surrounding host
tissues, and most importantly, no teratoma was observed. Forma-
tion of fibrosis was observed in all scaffolds implanted by trichrome
staining, with an indication of high fibrosis in cell-seeded scaffolds
than control scaffolds (Fig. 8b–8e). Mineralization was only detected
in scaffolds (PCL and PHT) seeded with hiPS-MSCs (Fig. 8d and 8e).
We further used micro-CT to quantify the ectopic bone formation.
Newly formed bones and typically rod-like trabeculae were observed
in all four groups (Fig. 9, left panel). Besides, the ectopic bone from
the PHT-iPS-MSCs group was more uniform than other groups
(Fig. 9, right panel). We then quantified the microarchitectures
among these four groups (Supplementary Table 2). However, due
to the limited number of animals used, the only significant diffe-
rences found were in the case of trabecular separation and trabe-
cular number between the iPS-MSC seeded PCL scaffolds and the
control PCL scaffolds.
Discussion
Over the pass few years, remarkable progress has been made in the
generation of clinically compliant and safer human iPSCs by means
of virus- and/or vector-free methods. The iPSCs we generated by
mRNA reprogramming closely recapitulated the characteristics of
human ESCs and are comparable to the iPSCs generated by the same
method from other groups7,8. We in this study further showed that
these iPSCs are an attractive stem cell source for deriving mesench-
ymal stem cells towards orthopedic applications.
Embryoid body (EB) formation is one of the most broadly used
methods for inducing embryonic stem cells (ESCs) or iPSCs towards
mesenchymal differentiation. However, the initial EB-mediated dif-
ferentiation is spontaneous and thus composing all kinds of somatic
cells along with the MSCs. Enrichment of MSCs by means of
cultivation in MSCs-inducing medium followed by FACS is com-
monly required after EB differentiation10,12,19,20. Embryoid body-
independent mesenchymal differentiation methods have been
developed and optimized during the last few years to facilitate the
induction of MSCs from human ESCs/iPSCs. Barberi et al. in 2005
described a simple method of deriving functional multipotent
mesenchymal precursors from hESCs by culturing the hESCs on
OP9 feeders in the presence of 20% heat-inactivated FBS in alpha
MEM medium followed by CD73-based FACS21. The efficiency of
CD73 positive cells achieved by their study was relatively low, an
average of 5%. Lim’s group applied a modified method by culturing
single hESCs on gelatin-coated plates in a conditional that are suit-
able for MSCs growth, which has greatly improved the efficiency of
deriving functional MSCs22,23. Repeated passaging by trypsinization
has been showed to enriched MSCs population16,22. Other modifica-
tions, such as coating tissue culture plate surface with fibrillar col-
lagen24 or supplemental small molecule inhibitor25, have been
showed to facilitate MSCs differentiation from hESCs/hiPSCs as
well. The hiPS-MSC-derivation method we used in this study is
similar to Yen et al. ’s, which was used to derive hES-MSCs16.
The hiPS-MSCs we generated approached almost 100% positive
for CD73 (from passage 3), recapitulated mesenchymal stem cell
markers and were capable of differentiating into mesenchymal
lineages (osteoblasts, adipocytes, and chondrocytes), consistent with
report from Yen et al.16. Most importantly, the iPS-MSCs are com-
patible with and functional for osteogenesis in 3D scaffolds both in
vitro and in vivo, suggesting that these cells can help evaluating and
improving the development of new nano-featured scaffolds in the
future. However, mechanisms of why functional MSCs, or mesench-
ymal progenitor cells named by Yen et al. in their study16, can effi-
ciently derived from iPSCs by serial culturing and trypsinization
needs further investigations. One possibilitymight be associated with
the serum that we used. However, since we used a different lot of
serum from Yen et al. (also from different suppliers), we speculate
Figure 4 | Tri-lineages differentiation of the hiPS-MSCs. (a) Alizarin red
staining of osteogenic mineralization (day 21). (b) Oil Red O staining of
small lipid droplets (day 21). (c) Toluidine blue staining of cartilage
positive cells (day 21).
www.nature.com/scientificreports
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Figure 5 | Osteogenesis with iPS-MSCs in 3D scaffolds in vitro. (a) SEM image of PHT scaffold shows hyaluronan/TCPmatrix covers and connects the
PCL scaffold fibers. (b, c) Confocalmicrographs of cell viability withCellTracker green andHoechst staining on PHT scaffolds after one day (b) and 7 days
culture (c). Green pixels: live cells; red pixels: nuclei. (d–f) Time-course measurement of ALP activity (d), calcium content (e).
Figure 6 | Analysis of osteoblast markers expression by qPCR. The expression of Runx2, ALP, Col1a1 and OC were determined by qPCR during osteo-
differentiation (triplicate experimental repeats). Time-course (7, 14, and 21 days) gene expression was analyzed in hiPS-MSCs-seeded PCL or PHT
scaffolds cultivated in proliferation medium (control) or osteogenic medium (OM). *, statistically significant between PCL-OM and PCL-control, PHT-
OM and PHT-control; #, statistically significant between PCL-OM and PHT-OM.
www.nature.com/scientificreports
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that the serum effect should not be main effector. However, the
choice and effect of serum for hiPS-MSCs differentiation needs
exploration in a future study. We have also investigated whether this
iPS-MSCs differentiation method can be applied to iPSCs generated
by other reprogramming method rather than mRNA reprogram-
ming. The same functional hiPS-MSCs were indeed successfully
generated from three lines of human iPSCs produced by lentivirus-
based reprogramming (data not shown).
Human pluripotent stem cells-derived mesenchymal stem cells
have the same in vitro and in vivo characteristics as MSCs derived
from adult tissues, such as bone marrow, fat, umbilical cord, and
others26,27. However, it has been consistently observed that ESCs/
iPSCs-derived MSCs have an advance in growth over adult
MSCs13,28. Higher telomerase activity and less senescence were
observed in pluripotent stem cells-derived MSCs as compared to
adult MSCs13. In this study, we have characterized the loss of plur-
ipotency-as seen with the loss of OCT3/4 and TRA-1-81 – along with
the loss of tumorigencity of the iPS-MSCs. However, we still
observed the express of Nanog in these iPS-MSCs. Nanog positive
adult MSCs or iPS-MSCs have been reported previously25,29. Recent
study by Han et al. found that expression of Nanog in MSCs was
crucial for maintaining MSC proliferation capacity and myogenic
differentiation potential30, suggesting the expression of Nanog in
the hiPS-MSCs derived by our method preserves the proliferative
and mesenchymal potential of MSCs to some extent.
Metal implants are widely used in orthopedic surgery, but they are
not bioresorbed and have risk of damage to surrounding bone due to
stress shielding31. Biodegradable materials have gained increased
interest as scaffold material because they can be fabricated for a wide
range of biomedical applications with a high processability, con-
trolled degradation, adjustablemechanical properties, and possibility
for modification32. Although polycaprolactone (PCL) scaffold is a
popular material since its degradation occurs naturally in the body’s
metabolism and the degradation compounds do not damage sur-
rounding tissue33, PCL is not biologically active it does not stimulate
stem cell bone formation. In this study, we also found that supple-
ment of hyaluronan and b-TCP to the PCL scaffolds (named PHT
scaffolds) could enhance the osteogenic capacity of iPS-MSCs,
including increase ALP activity, calcium mineralization and ECM,
as well as more uniform ectopic bone formation in vivo. More pre-
clinical (in large animals such as pigs) or even clinical trails of the
PHT scaffolds may allow this new scaffold to server as new bioma-
terial for orthopedic applications. The combination of iPS-MSCs and
scaffolds holds great potential for patient-specific orthopedic
Figure 7 | The hiPS-MSCs form calcified structures in 3D scaffolds in vitro. SEM images show extracellular matrix formation in the hiPS-MSCs The
expression ofseeded PCL (a) or PHT (b) scaffolds in proliferation medium (control), and the hiPS-MSCs seeded PCL (c) or PHT (d) scaffolds in
osteogenic medium (OM) after 21 days culture. Energy dispersive X-ray spectrometer analysis of calcified formation on scaffolds was showed in the right
panel. S, scaffold; ECM, extra cellular matrix.
www.nature.com/scientificreports
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therapy, as it was showed that differentiated cells from syngenetic
iPSCs could bypass the host immune response34. However, this
application should requires much more preclinical evaluation and
testing, including safety assessment and safer approach as it is in
other aspects28. Apart from that, our data and many other studies
suggest that the iPSCs are a great source of stem cells towards patient-
specific mesenchymal stem cell therapy.
Methods
Reprogramming of human fibroblasts (IMR90). Human primary fibroblasts
IMR90 were obtained from ATCC (catalog CCL-186). Reprogramming experiments
were performed in 6-well tissue culture plates coated with GlobalStem human feeders
at a cell density of 2.503 105 per well. The IMR90 cells were plated (100 K per well) in
Pluriton medium (Stemgent) supplemented with 200 ng/ml B18R (interferon
inhibitor from eBioscience) throughout the modified mRNA reprogramming
cocktail transfection. An RNA dose of 1.2 mg was delivered to each well using
RNAiMAX (Invitrogen) 4 hours prior to the daily medium change. RNAiMAX
transfection cocktails were assembled by diluting 100 ng/uL RNA 5X and 5 uL of
RNAiMAX per microgram of RNA 10X separately in DPBS without calcium or
magnesium. Clones of iPS cells were selected and transferred to fresh human feeder
coated plates after 18–20 days of modified mRNA transfection.
Mesenchymal differentiation of iPSCs without EB formation. For the derivation of
iPSC-MSCs, three days after splitting, iPS medium was replaced with MSC medium,
which consisted of DMEM-low glucose (Biological Industries), 2 mM L-Glutamine,
1% penicillin/streptomycin, and 10% FBS (Gibco). The MSC medium was changed
every 2 days. After 14 days culture, the cells were trypsinized (0.25% trypsin/1 mM
EDTA, Difco-Sigma) and expanded in MSC medium on 0.1% gelatin-coated dishes
(Becton Dickinson). When confluent (3–5 days), cells were harvested with 0.025%
trypsin-EDTA and then regularly passaged at a 153 ratio. Usually, after the third
trypsinization, a morphologically homogeneous population of fibroblast-like cells
became evident and was used in the analysis of MSC phenotypic characteristics and
differentiation potential.
Surface Antigen Analysis of iPS-MSCs. Cell surface antigens of human iPS-MSCs
were analyzed by flow cytometry. Cells (passage 3, 5, and 7) were harvested by
trypsinization from T150 flask followed by two washes with PBS (with 2% FBS). A
total of 5 3 105 cells were stained in a final volume of 100 ml PBS/2% FBS for 30
minutes at room temperature in the dark. The following murine-anti-human
antibodies was used at the manufacturer’s recommended concentration: anti-CD45
BD Horizon V450, anti-CD90 FITC, anti-CD105 PerCP-Cy5.5, anti-CD73 PE, and
anti-CD34 APC (all from BD Biosciences, San Jose, CA). As controls, fluorochrome
and concentration matched isotopes were used (all IgG1, BD Biosciences). Following
two washes in PBS/2%FBS, cells were resuspended in 1% formaldehyde in PBS while
vortex mixing. Cells were analyzed using a FACSAriaTM III (BD Biosciences)
equipped with a 375 nm, 488 nm, 561 nm, and 633 nm laser. For each sample 30,000
cells were collected and subsequently analyzed using FlowJo software (v. 9.3.3,
TreeStar Inc., Ashland, OR).
In vitro multipotent differentiation of iPS-MSCs. Multipotency of iPS-MSCs was
tested for differentiation along the osteogenic, chondrogenic, and adipogenic
lineages. The medium was replaced every 3-4 days for 21 days. The cells cultivated in
basal medium served as control. To induce osteogenic differentiation, cells were
cultured in osteogenic differentiation medium consisting of DMEM-high glucose
Figure 8 | Osteogenesis with hiPS-MSCs in 3D scaffolds in vivo. Picture of nude mice with subcutaneous implantation of scaffolds (a). Trichrome and
Alizarin Red staining of cell-free PCL (b) cell-free PHT (c) iPS-MSCs seeded PCL (d) and iPS-MSCs seeded PHT scaffolds (e) after implantation into
nude mice for 12 weeks. S, scaffolds; Positive Alizarin Red staining in (d) and (e) was pointed with stars.
www.nature.com/scientificreports
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(Invitrogen) supplemented with 10% FBS (Gibco), 290 nM ascorbic acid-2-
phosphate (Merck), 5 mM b-glycerophosphate (Sigma), and 100 nM
dexamethasone (Sigma) for 3 weeks. Calcium deposition was detected by Alizarin red
S (Sigma) following themanufacturer’s instructions. Alkaline phosphatase (ALP) was
stained with variamine blue B salt (Fluka) and 1-Naphthyl phosphate sodium salt
monohydrate (Merk). Adipogenic differentiation was induced by means of
adipogenesis inducing medium containing DMEM-high glucose (Invitrogen), 15%
horse serum (Sigma), and 100 nM dexamethasone (Sigma). Cells were examined for
the presence of lipid vacuoles by Oil Red O staining using standard techniques as
previously described (18). For chondrogenic differentiation, 2.5 3 105 cells were
centrifuged in a 15-mLpolypropylene Falcon tube to form a pellet which is cultured in
chondrogenic medium, consisting of DMEM-high glucose (Invitrogen), 50 mg/mL
ascorbic acid, 100 nM dexamethasone, 15100 ITS premix (BD Biosciences, San Jose,
CA), 40 mg/ml L-proline (Sigma-Aldrich), 10 ng/mL human recombinant TGFb3
(R&D systems). Presence of proteoglycan (PG) was documented by means of
toluidine blue staining.
Subcutaneous implantation surgical procedure. Seven-week-old NMRI-Nudemice
were purchased from Taconic, Ejby Denmark and housed under pathogen free
conditions at the Core Animal Facility of Aarhus University. All procedures were
performed according to the Animal Care and Use Committee guidelines at the
Aarhus University and approved by the Danish Experimental Animal Inspectorate
(License no. 2007/561-1407). Mice were anesthetized with inhaled isoflurane 3,75%.
After inducing general anesthesia, two longitudinal skin incisions were made on the
dorsal surface of eachmouse, and two subcutaneous pockets were created, into which
an iPS-MSC-scaffold construct and an acellular control scaffold were inserted. The
skin was closed with interrupted 6-0 nylon sutures. Postsurgical pain treatment was
performed by adding buprenorphine to the drinking water (TemgesicH, Reckitt
Benckiser Healthcare, England) at a dose corresponding to 0.7–1.4 mg/kg for two
days. After 12 weeks, animals were euthanized and the implants were fixed in 10%
neutral buffered formalin for histological and micro-CT analysis.
Other methods used in this study were provided in supplementary file. Primers
used for Q-PCR were listed in Supplementary Table 1.
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